|
Abnormal facility in opposing the shoulders
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
|
Abnormal sacrum morphology
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
|
Abnormality of dental enamel
|
0.100 |
Biomarker
|
group |
HPO |
|
|
|
|
Abnormality of epiphysis morphology
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
|
Abnormality of the metacarpal bones
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
|
Abnormality of the ribs
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
|
Absent frontal sinuses
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
|
Absent paranasal sinuses
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
|
Acampomelic Campomelic Dysplasia
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
We tested this approach in three patients with complex chromosomal translocations: The first had craniofacial abnormalities and an apparently balanced t(2;3)(p15;q12) translocation; the second has cleidocranial dysplasia (OMIM 119600) associated with a t(2;6)(q22;p12.3) translocation and a breakpoint in RUNX2 on chromosome 6p; and the third has acampomelic campomelic dysplasia (OMIM 114290) associated with a t(5;17)(q23.2;q24) translocation, with a breakpoint upstream of SOX9 on chromosome 17q.
|
21890680 |
2011 |
|
Acute lymphocytic leukemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Finally, we constructed a gene expression- and interaction-based outcome predictor consisting of 27 genes (including GRB2, GAB1, GLI1, IRS1, RUNX2, and SPP1), which correlated with overall survival in BCR-ABL-positive adult ALL (P = .0001), independent of age (P = .25) and WBC count at presentation (P = .003).
|
17312329 |
2007 |
|
Acute myelomonocytic leukemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Hsp27 was abundantly expressed in newly diagnosed AML-M4/M5 bone marrow mononuclear cells (BMMCs) and THP-1, OCI/AML-3 leukemia cell lines.
|
23404246 |
2013 |
|
Acute Promyelocytic Leukemia
|
0.040 |
GeneticVariation
|
disease |
BEFREE |
Recently, differentiation therapy of acute promyelocytic leukemias (AML3 subtype) with all-trans-retinoic acid has been shown to be an efficient alternative to chemotherapy.
|
1317749 |
1992 |
|
Acute Promyelocytic Leukemia
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
However, only the combinations of all-trans retinoic acid or arsenic trioxide with chemotherapy have been successful, and only in treating acute promyelocytic leukemia (also called AML3).
|
20368581 |
2010 |
|
Acute Promyelocytic Leukemia
|
0.040 |
GeneticVariation
|
disease |
BEFREE |
ATRA is strikingly effective in acute promyelocytic leukemia (the AML3 subtype) inducing a high incidence of complete remissions.
|
8309256 |
1994 |
|
Acute Promyelocytic Leukemia
|
0.040 |
Biomarker
|
disease |
BEFREE |
Finally, knockdown of miR-128a in OCI-AML3 and in APL/AML leukemic cells (by transfection and lentiviral infection, respectively) induced myeloid cell differentiation and increased expression of Lin28A, EGR2, ZFP36 and ANXA1, reverting myeloid differentiation blockage.
|
28569789 |
2017 |
|
Adenocarcinoma
|
0.040 |
AlteredExpression
|
group |
BEFREE |
Examination of RUNX2 expression in esophageal cancer showed its upregulation concomitant with the development of dysplasia and continued expression in adenocarcinoma.
|
28631378 |
2018 |
|
Adenocarcinoma
|
0.040 |
Biomarker
|
group |
BEFREE |
A microRNA/Runx1/Runx2 network regulates prostate tumor progression from onset to adenocarcinoma in TRAMP mice.
|
27634876 |
2016 |
|
Adenocarcinoma
|
0.040 |
AlteredExpression
|
group |
BEFREE |
The clinical significance of these findings is supported by human tissue microarray studies of prostate tumors at stages of cancer progression, in which Runx2 is expressed in both adenocarcinomas and metastatic tumors.
|
19915614 |
2010 |
|
Adenocarcinoma
|
0.040 |
Biomarker
|
group |
BEFREE |
Moreover, transforming growth factor-β induced RUNX2/ p57 overexpression and specific RUNX2 knockdown supported a role for RUNX2 in epithelial mesenchymal transition, which was demonstrated through loss of function assays in adenocarcinoma A549 lung cancer cell line.
|
31109257 |
2019 |
|
Adenocarcinoma of large intestine
|
0.010 |
Biomarker
|
disease |
BEFREE |
LINC01638 silencing inhibits cancer cell proliferation in colorectal adenocarcinoma through interaction with RUNX2.
|
31059049 |
2019 |
|
Adenocarcinoma of lung (disorder)
|
0.010 |
Biomarker
|
disease |
BEFREE |
Cellular proliferation of ALDH3A1-expressing lung adenocarcinoma (A549) and glioblastoma (SF767) cell lines, as well as ALDH3A1 non-expressing lung fibroblast (CCD-13Lu) cells, is unaffected by treatment with CB29 and its analogues alone.
|
24677340 |
2014 |
|
Adenomatous Polyposis Coli
|
0.010 |
Biomarker
|
disease |
BEFREE |
The results of our study and the comprehensive review of the literature show that pathways of forming supernumerary teeth appear to involve APC and RUNX2, the genes responsible for familial adenomatous polyposis syndrome and cleidocranial dysplasia, respectively.
|
27706911 |
2017 |
|
Adolescent idiopathic scoliosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
The expression of type X collagen, Runx2, and Runx2 mRNA, the cell density of type X collagen and Runx2 positive chondrocytes, and histological changes between convex side and concave side of the vertebral growth plate indicated that the vertebral growth plate was affected by mechanical forces, which was a secondary change and could contribute to progression of adolescent idiopathic scoliosis.
|
20073986 |
2010 |
|
Adult Acute Lymphocytic Leukemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Finally, we constructed a gene expression- and interaction-based outcome predictor consisting of 27 genes (including GRB2, GAB1, GLI1, IRS1, RUNX2, and SPP1), which correlated with overall survival in BCR-ABL-positive adult ALL (P = .0001), independent of age (P = .25) and WBC count at presentation (P = .003).
|
17312329 |
2007 |
|
Adult Glioblastoma
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Cellular proliferation of ALDH3A1-expressing lung adenocarcinoma (A549) and glioblastoma (SF767) cell lines, as well as ALDH3A1 non-expressing lung fibroblast (CCD-13Lu) cells, is unaffected by treatment with CB29 and its analogues alone.
|
24677340 |
2014 |